DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Press-release

Pharmacia and Pfizer's Celebrex and Merck's Vioxx Will Soon Compete with Second-Generation Selective COX-2 Inhibitors in the Osteoarthritis Drug Market, According to a Decision Resources Study

Pharmacia and Pfizer's Celebrex and Merck's Vioxx Will Soon Compete with Second-Generation Selective COX-2 Inhibitors in the Osteoarthritis Drug Market, According to a Decision Resources Study

All eyes have been on the first selective COX-2 inhibitors, celecoxib (Pharmacia and Pfizer's Celebrex) and rofecoxib (Merck's Vioxx), for the...

READ ARTICLE

Press-release

Decision Resources Elects Two Vice Presidents

Decision Resources Elects Two Vice Presidents

Decision Resources, Inc., a pharmaceutical research and consulting firm, is pleased to announce the election of two new Vice Presidents-James...

READ ARTICLE

Press-release

Decision Resources Releases Study Illustrates How Pharmaceutical Companies Can Mine Clinical Development Programs for Strategic Product Advantages

Decision Resources Releases Study Illustrates How Pharmaceutical Companies Can Mine Clinical Development Programs for Strategic Product Advantages

Using Clinical Trials to Strategic Advantage is a new DR Report from Decision Resources, Inc., that explains how clinical trials can be invaluable...

READ ARTICLE

Press-release

Decision Resources Study on Post-Myocardial Infarction Finds AstraZeneca's Rosuvastatin May Become the Statin of Choice by 2005

Decision Resources Study on Post-Myocardial Infarction Finds AstraZeneca's Rosuvastatin May Become the Statin of Choice by 2005

Post-Myocardial Infarction is a new study from Decision Resources, Inc., that examines how the need for better and novel cardioprotective agents to...

READ ARTICLE

Press-release

Novel Asthma Therapies and Combination Agents Will Vie for Market Share, According to a Decision Resources Study

Novel Asthma Therapies and Combination Agents Will Vie for Market Share, According to a Decision Resources Study

Asthma is a new Decision Resources study that examines novel drug development efforts arising from a wealth of research into the pathophysiology of...

READ ARTICLE